Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance

Acta histochemica
Changping WuNing Xu

Abstract

The present study examined programmed death-1 ligand-1 (PD-L1) detected by immunohistochemical labeling in 102 cases of human gastric carcinoma, 10 adenoma and 10 normal tissues. The relationship between PD-L1 immunolocalization and clinical pathological features, as well as the prognosis of gastric carcinoma, was explored. There was no PD-L1 detectable in normal gastric tissues and very weak immunolabeling in gastric adenomas, but it could be detected in 42.2% of gastric carcinoma tissues. There was no correlation between PD-L1 immunolocalization and patient age, sex, tumor location or the degree of tumor differentiation in the gastric carcinomas. However, PD-L1 immunodetection was significantly correlated to tumor size, invasion, lymph node metastasis and survival time of patients. PD-L1 immunolabeling was significantly enhanced (P<0.01) when the tumor infiltrated into the deep muscular layers, with lymph node metastasis or survival time of less than 2 years, Moreover, multivariate analysis demonstrated that PD-L1 immunodetection could be used as an independent factor to evaluate the prognosis of gastric carcinoma.

References

Apr 21, 1999·Current Opinion in Cell Biology·C A Chambers, J P Allison
Jun 3, 2000·Annual Review of Immunology·L Fong, E G Engleman
Jun 3, 2000·Annual Review of Immunology·J BanchereauK Palucka
Apr 3, 2001·The Journal of Experimental Medicine·S Y TsengH Tsuchiya
May 11, 2002·Nature Reviews. Immunology·Drew M Pardoll
Sep 10, 2002·Proceedings of the National Academy of Sciences of the United States of America·Yoshiko IwaiNagahiro Minato
Apr 22, 2003·Nature Medicine·Tyler J CurielWeiping Zou
May 30, 2003·Gastric Cancer : Official Journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·David M Roder
Mar 29, 2005·Journal of Huazhong University of Science and Technology. Medical Sciences = Hua Zhong Ke Ji Da Xue Xue Bao. Yi Xue Ying De Wen Ban = Huazhong Keji Daxue Xuebao. Yixue Yingdewen Ban·Ye YuanGuimei Zhang
Apr 20, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Yuichiro OhigashiYoshiyuki Nakajima

❮ Previous
Next ❯

Citations

Dec 30, 2006·Cancer Immunology, Immunotherapy : CII·Christian Blank, Andreas Mackensen
Aug 21, 2010·Cancer Immunology, Immunotherapy : CII·Jingting JiangXueguang Zhang
Jun 15, 2012·Cancer Immunology, Immunotherapy : CII·Barbara Seliger, Dagmar Quandt
Jun 1, 2011·Cancer Microenvironment : Official Journal of the International Cancer Microenvironment Society·Sytse J Piersma
Aug 1, 2013·Clinical & Translational Immunology·David E GyorkiCharlotte E Ariyan
Dec 17, 2009·The Journal of Experimental Medicine·Loise M FranciscoArlene H Sharpe
Sep 29, 2011·The Cancer Journal·Michael PostowJedd D Wolchok
Jan 5, 2008·Annual Review of Immunology·Mary E KeirArlene H Sharpe
Mar 6, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Mario Sznol, Lieping Chen
Dec 4, 2013·Cancer Immunology, Immunotherapy : CII·Christian J MaineSadaf Ghaem-Maghami
Nov 19, 2013·Pathology Oncology Research : POR·Xiao-Juan ChenWei-Chang Chen
Feb 20, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Ching-Yao YangPan-Chyr Yang
May 14, 2014·Oral Oncology·Dan P Zandberg, Scott E Strome
Mar 16, 2007·Proceedings of the National Academy of Sciences of the United States of America·Junzo HamanishiShingo Fujii
Apr 14, 2012·Journal of Biomedicine & Biotechnology·Daria CapeceEdoardo Alesse
Aug 2, 2014·Breast Cancer Research and Treatment·S MuenstS D Soysal
Oct 24, 2014·Immunotherapy·Hans Anton SchlößerMichael von Bergwelt-Baildon
Oct 15, 2014·Medical Oncology·Dong JiangXue-guang Zhang
Feb 21, 2013·Expert Opinion on Biological Therapy·Omid Hamid, Richard D Carvajal
Feb 13, 2016·International Journal of Clinical Oncology·Shunsuke Chikuma
Oct 29, 2013·FEBS Letters·Chrisann Kyi, Michael A Postow
Jan 17, 2016·International Immunopharmacology·Yan LuanTing Xu
Jun 14, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Aaron Scott MansfieldEugene D Kwon
Mar 17, 2016·Human Pathology·Christelle Combaz-LairSylvie Lantuejoul
Aug 13, 2014·Journal of Translational Medicine·Xiao-Dong LiJing-Ting Jiang
Nov 11, 2014·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Hidenobu IshiiTomoaki Hoshino
Jun 2, 2014·Hematology/oncology Clinics of North America·Jarushka NaidooJedd D Wolchok
Feb 24, 2016·International Journal of Clinical Oncology·Junzo HamanishiIkuo Konishi
Nov 28, 2012·Journal de gynécologie, obstétrique et biologie de la reproduction·S HanssenD Vinatier
Jan 19, 2016·Molecular Oncology·Lienlaf MVillagra A
Jan 11, 2016·Journal of Internal Medicine·S MuenstS Hoeller
Jul 19, 2011·Hematology/oncology Clinics of North America·Jacalyn Rosenblatt, David F McDermott
May 4, 2010·Autoimmunity Reviews·Ravi K DineshRam Pyare Singh

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis